Overview

Guadecitabine Extension Study

Status:
Active, not recruiting

Trial end date:
2021-08-31

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label extension study for subjects who participated in a previous Astex-sponsored guadecitabine clinical study (including but not limited to SGI-110-01, SGI-110-04, SGI-110-06, and SGI-110-07).

Phase:

Phase 2

Details

Lead Sponsor:

Astex Pharmaceuticals
Astex Pharmaceuticals, Inc.

Treatments:

Azacitidine
Guadecitabine